What new gene-editing technology, designed to minimize unwanted edits to DNA, was announced by UC San Diego researchers in March 2026?

In March 2026, researchers at UC San Diego announced a significant advancement in gene-editing technology: ME-ABEs. This new tool, which stands for minimally evolved adenine base editors, was developed to enhance the precision of genetic modifications by drastically reducing unintended alterations to DNA. The innovation addresses a long-standing challenge in gene editing, where previous methods could sometimes make unwanted "bystander edits" to bases near the intended target, potentially leading to unforeseen complications or compromising the safety of therapeutic applications.

Base editing itself is a sophisticated form of gene editing that chemically changes individual DNA bases without creating double-strand breaks, a process associated with earlier CRISPR-Cas9 technologies that could introduce undesirable insertions or deletions. Adenine base editors (ABEs), a specific type of base editor, are designed to convert adenine (A) to guanine (G). While effective, a limitation known as the "bystander effect" meant that these editors could sometimes modify multiple adjacent adenine bases, even if only one was targeted. Efforts to narrow the editing window to prevent these bystander edits often resulted in a loss of efficiency for the desired on-target edit.

The breakthrough with ME-ABEs, led by Alexis Komor's lab at UC San Diego, lies in its ability to "decouple" editing efficiency from the editing window. By carefully reverting certain mutations in existing ABEs, the researchers created a more refined tool that maintains high efficiency for the intended genetic change while significantly minimizing off-target bystander edits. For example, one version, ABE7.10-HRHSK, demonstrated over an 11-fold reduction in off-target editing compared to commonly used variants. This enhanced precision makes ME-ABEs invaluable for accurately modeling genetic diseases and developing safer, more effective personalized medicines.